Literature DB >> 18723062

Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.

Paolo Bonanni1, Sara Boccalini, Angela Bechini, Kurt Banz.   

Abstract

An economic evaluation of universal varicella vaccination in Italy was performed to assess the potential clinical and economic effects of three different strategies versus no vaccination. By means of the EVITA model, vaccination with two doses in toddlers only (1-1.5 years), adolescents only (13 years) and toddlers with adolescents catch-up programmes were simulated. All universal varicella vaccination strategies including toddlers (with or without an adolescent catch-up programme) turned out to be highly effective in reducing the burden of disease due to varicella. In addition, they lead to significant net savings from the societal perspective but to higher costs compared to return of investment from National Health Service perspective. The huge economic burden of hospitalised uncomplicated varicella cases registered in Italy can partially explain these highly beneficial findings for the societal perspective. Overall, our analysis confirmed the favourable clinical and economic impact of routine varicella vaccination with two doses of vaccine in Italy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723062     DOI: 10.1016/j.vaccine.2008.07.096

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Economic evaluation of Varicella vaccination: results of a systematic review.

Authors:  Brigid Unim; Rosella Saulle; Sara Boccalini; Cristina Taddei; Vega Ceccherini; Antonio Boccia; Paolo Bonanni; Giuseppe La Torre
Journal:  Hum Vaccin Immunother       Date:  2013-07-03       Impact factor: 3.452

Review 2.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

3.  Safety of a second dose of varicella vaccine administered at 4 to 6 years of age in healthy children in Argentina.

Authors:  Diego Fridman; Andrea Monti; Marie-Claude Bonnet; Judith Armoni; Daniel Stamboulian
Journal:  Hum Vaccin       Date:  2011-10-01

4.  The Economic Value of Vaccination: Why Prevention is Wealth.

Authors: 
Journal:  J Mark Access Health Policy       Date:  2015-08-12

5.  The burden of varicella from a parent's perspective and its societal impact in The Netherlands: an Internet survey.

Authors:  Judith H Wolleswinkel-van den Bosch; Anouk M Speets; Hans C Rümke; Pearl D Gumbs; Sander C Fortanier
Journal:  BMC Infect Dis       Date:  2011-11-17       Impact factor: 3.090

6.  How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decision-makers and stakeholders? The ISPOR Rome Chapter Project.

Authors:  R Gasparini; F S Mennini; D Panatto; P Bonanni; A Bechini; W Ricciardi; C DE Waure; A Marcellusi; A Cicchetti; M Ruggeri; S Boccalini
Journal:  J Prev Med Hyg       Date:  2015

Review 7.  Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.

Authors:  Oliver Damm; Bernhard Ultsch; Johannes Horn; Rafael T Mikolajczyk; Wolfgang Greiner; Ole Wichmann
Journal:  BMC Public Health       Date:  2015-06-05       Impact factor: 3.295

Review 8.  Varicella vaccination in Europe - taking the practical approach.

Authors:  Paolo Bonanni; Judith Breuer; Anne Gershon; Michael Gershon; Waleria Hryniewicz; Vana Papaevangelou; Bernard Rentier; Hans Rümke; Catherine Sadzot-Delvaux; Jacques Senterre; Catherine Weil-Olivier; Peter Wutzler
Journal:  BMC Med       Date:  2009-05-28       Impact factor: 8.775

9.  National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learning.

Authors:  Walter Ricciardi; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2015-09-14

10.  The societal role of lifelong vaccination.

Authors:  Maarten J Postma; Stuart Carroll; Alexandra Brandão
Journal:  J Mark Access Health Policy       Date:  2015-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.